Most FDA scientists opposed plan to ease access to unproven peptide drugs
Most FDA scientific staff opposed a plan to make unproven peptide drugs easier to get, and had little say in writing it, according to six people familiar with the policy.
Most scientific staff at the Food and Drug Administration opposed a plan to give people in the U.S. easier access to unproven peptide drugs, according to six people familiar with its development. The peptides are favored by Health Secretary Robert F. Kennedy Jr.
Those people said agency scientists had limited input in drafting the policy. PBS NewsHour carried the report as an AP story. The Guardian reported the same account.
The Guardian reports that the Department of Health and Human Services posted the policy document online on Wednesday. It covers a handful of injectable peptides promoted in the wellness industry for building muscle, healing injuries and boosting energy.
The Guardian also says the effort met fierce pushback from agency scientists.
Reported by
- The GuardianFDA scientists opposed Trump administration’s move to ease peptide accessWed, Oct 28, 2:35 PM EDT
- PBS NewsHourAP report: FDA scientists opposed the Trump administration's move to ease peptides accessWed, Oct 28, 5:20 PM EDT
This story was written by AI using only the reports listed above, and published without a person reviewing it first. It is rewritten as new reports arrive. Read the original reporting for full detail. Spot an error? Tell us.